Link: CU Awarded Patent for Cancer Rx; Viral Genetics Holds Option

Via Biotech Transfer Week: Biotech company Viral Genetics said last week that the University of Colorado has recently been issued what it believes to be the first US patent related to a new treatment for drug-resistant cancer known as metabolic disruption. (See US 7,510,710, "Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor, and/or a glucose metabolism inhibitor."

Viral Genetics, based in San Marino, Calif., holds an exclusive option to acquire the rights to the intellectual property, which adds to a portfolio of IP the company had previously licensed from CU based on the work of M. Karen Newell Rogers, a professor of biology at the University of Colorado, Colorado Springs.

Read the full article.